Clinical Trials
25 trialsNCT04855435 2026-05-12
Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours
MonTa Biosciences ApS
Phase 1 Recruiting
NCT05496686 2026-04-03
Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
Modulation Therapeutics, Inc.
Phase 1 Active not recruiting
NCT04328844 2026-03-30
A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
Phase 1 Active not recruiting
NCT07076550 2026-03-16
A Phase 1-1b Study to Evaluate the Safety, Efficacy and Dosimetry of Study Drug A9-3408 in Subjects With Metastatic Melanoma
Alpha-9 Oncology USA Inc.
Phase 1 Recruiting
NCT04336241 2026-02-27
Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid Tumors
Replimune, Inc.
Phase 1 Active not recruiting
NCT03746431 2026-01-07
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Fusion Pharmaceuticals Inc.
Phase 1 Terminated
NCT06022029 2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1 Recruiting
NCT05047536 2025-12-19
KZR-261 in Subjects With Advanced Solid Malignancies
Kezar Life Sciences, Inc.
Phase 1 Terminated
NCT04935229 2025-10-22
Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma
TriSalus Life Sciences, Inc.
Phase 1 Terminated
NCT06805825 2025-09-23
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
Phase 1 Recruiting
NCT05576077 2025-03-10
STARLING
Turnstone Biologics, Corp.
Phase 1 Terminated
NCT04879017 2024-04-25
FHD-286 in Subjects With Metastatic Uveal Melanoma
Foghorn Therapeutics Inc.
Phase 1 Terminated
NCT04904120 2023-11-07
TIMAR1
Perspective Therapeutics
Phase 1 Completed
NCT03408587 2023-05-06
CLEVER
Viralytics
Phase 1 Completed
NCT00986661 2022-11-02
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
Provectus Pharmaceuticals
Phase 1 Unknown
NCT04551352 2022-10-03
A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas
Hoffmann-La Roche
Phase 1 Completed
NCT02601378 2022-09-29
A Phase I Study of LXS196 in Patients With Metastatic Uveal Melanoma.
Novartis
Phase 1 Terminated
NCT03297424 2022-07-25
A Study of PLX2853 in Advanced Malignancies.
Opna Bio LLC
Phase 1 Completed
NCT02315066 2022-04-21
Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Pfizer
Phase 1 Completed
NCT03652077 2021-11-15
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
Incyte Corporation
Phase 1 Completed
NCT01430416 2020-12-19
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
Novartis
Phase 1 Completed
NCT02771340 2020-10-01
Study Evaluating Single and Repeated Intravitreal Doses of ICON-1 in Patients With Uveal Melanoma
Iconic Therapeutics, Inc.
Phase 1 Completed
NCT02029690 2020-09-25
TRAP
Polaris Group
Phase 1 Terminated
NCT01665183 2016-02-25
Ph 1 Trial of ADI-PEG 20 Plus Cisplatin in Patients With Metastatic Melanoma
Polaris Group
Phase 1 Completed
NCT00471133 2011-06-07
Safety and Immunogenicity of a Melanoma DNA Vaccine Delivered by Electroporation
Ichor Medical Systems Incorporated
Phase 1 Completed